July 09, 2012

to-BBB awarded European FP7 Funding

to-BBB awarded EUR 1.25 million European FP7 funding to develop treatments for inherited retinal diseases

to-BBB, the Dutch brain drug delivery company, has been awarded funding of EUR 1.25 million by the European Commission’s 7th Framework Programme as part of a EUR 5 million consortium project for the preclinical development of novel treatments for inherited retinal degenerative diseases. The consortium additionally consists of Coordinator University of Tübingen (Germany), SME Biolog (Germany), University of Modena and Reggio Emilia (Italy) and Lund University (Sweden).

The consortium aims to develop drugs and drug delivery systems for the treatment of inherited photoreceptor degeneration up to the clinical stage. These orphan diseases often display a dysregulated cGMP metabolism or signaling, which could be counteracted by cyclic nucleotide analogues. The German Small Medium Enterprise (SME) Biolog is specialized in the development of cyclic nucleotide based drugs, and to-BBB will focus on the targeted delivery of these compounds across the blood-retinal barrier, a barrier with similar characteristics as the blood-brain barrier. The three research institutes from Germany, Italy and Sweden have a long-standing record of studying photoreceptor degenerative mechanisms and testing and evaluating of drug treatment effects.

[PROPOSAL] “Supported by funding from the European Framework Programme, this consortium has great potential to develop therapeutic options for inherited degenerative diseases of the retina.” says Coordinator François Paquet-Durand

“We feel this is an excellent opportunity for to-BBB to explore the applicability of the G-Technology® platform in the blood-retinal barrier,” said Pieter Gaillard, Chief Scientific Officer at to-BBB. “With this consortium we have a unique opportunity to develop orphan drugs for patients with these debilitating eye diseases.”

About inherited photoreceptor degeneration

Inherited photoreceptor degeneration diseases (including Retinitis Pigmentosa, Lebers Congenital Amaurosis, Achromatopsia) significantly contribute to visual impairment in both the EU and globally. It is estimated that these inherited diseases affect one in every 2000 individuals worldwide. For the Retinitis Pigmentosa group of diseases, mutations in over 50 genes are already identified as disease causing; however, there is still no effective treatment available.

About to-BBB

to BBB is a clinical stage biotechnology company focusing on enhanced drug delivery across the blood-brain barrier. The Company is developing novel treatments for devastating brain disorders, such as brain cancer, neurodegenerative diseases and lysosomal storage diseases, by combining existing drugs with the G Technology®, to BBB’s proprietary brain delivery platform. This technology combines the widely used drug delivery approach of pegylated liposomes with the endogenous tripeptide glutathione as targeting ligand in a novel and safe way. Together with several top tier pharma and biotech companies, to BBB is investigating the versatility of the G Technology for drugs that are unable to reach the brain at systemically tolerable therapeutic doses. to BBB is applying the G Technology for the delivery of doxorubicin for the treatment of brain cancer as its internal lead product 2B3 101.

to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).


to-BBB technologies BV
Niels Bohrweg 11
2333 CA Leiden
The Netherlands

Willem van Weperen, MSc, MBA
Chief Executive Officer
Phone: +31 71 3322252
E-mail: WillemVanWeperen(at)toBBB.com

Pieter Gaillard, PhD
Chief Scientific Officer
Phone: +31 71 3322252
E-mail: PieterGaillard(at)toBBB.com



Download the press release [PDF, 320 kByte]